69 related articles for article (PubMed ID: 37082728)
1. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
Res Sq; 2023 Mar; ():. PubMed ID: 36945511
[TBL] [Abstract][Full Text] [Related]
2. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.
Pal D; Vann KR; Joshi S; Sahar NE; Morales GA; El-Gamal D; Kutateladze TG; Durden DL
iScience; 2021 Sep; 24(9):102931. PubMed ID: 34557659
[TBL] [Abstract][Full Text] [Related]
3. SENP3 Promotes Mantle Cell Lymphoma Development through Regulating Wnt10a Expression.
Ma YN; Zou YD; Liu ZL; Wu GX; Zhou YZ; Luo CX; Huang XT; Xie ML; Xu SN; Li X
Curr Med Sci; 2024 Feb; 44(1):134-143. PubMed ID: 38273178
[TBL] [Abstract][Full Text] [Related]
4. Pirtobrutinib: a promising therapy for overcoming the resistance of ibrutinib in mantle cell lymphoma.
Fatima SK; Khan S; Mughal ZUN; Rangwala HS; Rangwala BS; Siddiq MA; Ali M; Farah AA
Ann Med Surg (Lond); 2024 Jun; 86(6):3189-3191. PubMed ID: 38846878
[No Abstract] [Full Text] [Related]
5. Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL.
Killock D
Nat Rev Clin Oncol; 2024 May; ():. PubMed ID: 38789564
[No Abstract] [Full Text] [Related]
6. SDC2 Stabilization by USP14 Promotes Gastric Cancer Progression through Co-option of PDK1.
You L; Dou Y; Zhang Y; Xiao H; Lv H; Wei GH; Xu D
Int J Biol Sci; 2023; 19(11):3483-3498. PubMed ID: 37496999
[TBL] [Abstract][Full Text] [Related]
7. Nuclear transport maintenance of USP22-AR by Importin-7 promotes breast cancer progression.
Cai GX; Kong WY; Liu Y; Zhong SY; Liu Q; Deng YF; Ye GL
Cell Death Discov; 2023 Jul; 9(1):211. PubMed ID: 37391429
[TBL] [Abstract][Full Text] [Related]
8. A wholesale approach to disarm multiple myeloma.
Cenci S
Blood Adv; 2023 Jun; 7(12):2938-2939. PubMed ID: 37368455
[No Abstract] [Full Text] [Related]
9. Inferring cell-type-specific causal gene regulatory networks during human neurogenesis.
Aygün N; Liang D; Crouse WL; Keele GR; Love MI; Stein JL
Genome Biol; 2023 May; 24(1):130. PubMed ID: 37254169
[TBL] [Abstract][Full Text] [Related]
10. Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel.
Wang H; Teng X; Lin Y; Jiang C; Chen X; Zhang Y
Discov Oncol; 2023 May; 14(1):82. PubMed ID: 37243787
[TBL] [Abstract][Full Text] [Related]
11. Potential Biomarkers for Parkinson Disease from Functional Enrichment and Bioinformatic Analysis of Global Gene Expression Patterns of Blood and Substantia Nigra Tissues.
Elango R; Banaganapalli B; Mujalli A; AlRayes N; Almaghrabi S; Almansouri M; Sahly A; Jadkarim GA; Malik MZ; Kutbi HI; Shaik NA; Alefishat E
Bioinform Biol Insights; 2023; 17():11779322231166214. PubMed ID: 37153842
[TBL] [Abstract][Full Text] [Related]
12. Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1.
Zhou J; Lei Z; Chen J; Liao S; Chen Y; Liu C; Huang S; Li L; Zhang Y; Wang P; Huang Y; Li J; Liang H
Clin Transl Med; 2023 May; 13(5):e1260. PubMed ID: 37151195
[TBL] [Abstract][Full Text] [Related]
13. USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.
Zhang N; Zhang H; Yang X; Xue Q; Wang Q; Chang R; Zhu L; Chen Z; Liu X
BMC Cancer; 2024 Feb; 24(1):237. PubMed ID: 38383348
[TBL] [Abstract][Full Text] [Related]
14. USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1.
Zhang Y; Lu P; Jin S; Zhang J; Zhou Y
Int J Med Sci; 2023; 20(5):616-626. PubMed ID: 37082728
[No Abstract] [Full Text] [Related]
15. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
16. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
17. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A; Sandoval N; Das M; Pillai R; Chen L; Chen RW; Amin HM; Wang M; Marcucci G; Weisenburger DD; Rosen ST; Pham LV; Ngo VN
Oncotarget; 2016 Nov; 7(45):73558-73572. PubMed ID: 27713153
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Hershkovitz-Rokah O; Pulver D; Lenz G; Shpilberg O
Br J Haematol; 2018 May; 181(3):306-319. PubMed ID: 29359797
[TBL] [Abstract][Full Text] [Related]
19. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
Wang K; Huang X; Di Liberto M; Chen-Kiang S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):809-823. PubMed ID: 32861279
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
